ClinicalTrials.gg
Status unknownNCT04609059Updated Oct 30, 2020

First-in-Patient Study for Sing le Dose of M201-A Hydrochloride Injection in Japanese Patients With Paroxysmal Atrial Fibrillation

A Phase 2 interventional study of M201-A Injection and Placebo in Paroxysmal Atrial Fibrillation, sponsored by Kitasato University. Status unknown at 5 sites in Japan. Open to participants aged 20 Years to 84 Years. Per ClinicalTrials.gov, last updated 2020-10-30.

Sponsored by Kitasato University · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Oct 2020), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled May 2019, registered Sep 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
20 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 84 studies in Atrial Fibrillation with a site in Japan — 7 open to participants now, 13 under way, 3 of them phase 3. Atrial Fibrillation · Japan.

Planned enrollment
52nd of 55
42 · median 500
Started
2019
with 4 others
Phase 2
11 of 84
none open now
Registered
70th of 84
by date

Among the 84 studies in Atrial Fibrillation with a site in Japan, this one is the 52nd largest by planned enrollment of the 55 interventional ones that give a count, is one of 5 that started in 2019, is one of 11 in phase 2, and was the 70th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

7 of the 84 studies in Atrial Fibrillation with a site in Japan are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 20 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Atrial Fibrillation with a site in Japan, or all of them as a file.
02

Study summary

First-in-Patient Study for sing le dose of M201-A hydrochloride injection in Japanese patients with paroxysmal atrial fibrillation.

03

Conditions studied

  • Paroxysmal Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
20 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) Japanese (male, female) adult with symptomatic paroxysmal atrial fibrillation (AF)
  • Written must be obtained on a voluntary basis before any assessment is performed.

    (2) Age: 20 to less than 85 years of age (3) Weight: 40 kilograms(kg) or more : 18.5 to less than 28.0 on screening examination(screening) (4) Past AF History: Event(s) as symptomatic AF with (at least) 2 hours or more AF lasting has (have) occurred at least once or more a half year (6 months) prior to the screening.

    (5) Occurrence time of the latest AF: Record(s) of the patient portable electrocardiograph shows evidence to support that the latest AF has occurred within 3 hours to less than 3 days (72 hours) prior to an administration of the product.

    (6) The AF lasting prior to the administration: 12 lead just prior to the administration shows that AF has not stopped.

    (7) Excluded medication: Based on propositions of a principal investigator or a co-investigator(s), a patient can consent for discontinuation of below antiarrhythmic agents (the Vaughan-Williams classification) for at least 7 days after administration since an advanced registration. Nonetheless, if a period between the advanced registration and the administration is less than 7 days, it should be confirmed those agent has unadministered during 7 days prior to the administration.

[Vaughan-Williams classification] Antiarrhythmic drug group I Antiarrhythmic drug group III Antiarrhythmic drug group IV Bepridil (8) Excluded administration of amiodarone: It should be confirmed that amiodarone hydrochloride is not unadministered within one (1) year before the screening.

Exclusion criteria

Exclusion Criteria:

  • (1) Heart failure ( II, III, IV). Excluding palpitations induced by atrial fibrillation (AF) (2) Any atrioventricular block of first, second or third degree at the time of sinus rhythm (3) Any risk factor leads to Torsades de Pointes (TdP)

    1. [0]: 440 ms or more in standard 12-lead at the time of sinus rhythm within 3 months prior to administration
    2. Hypokalemia or suspected to be hypokalemia:

      One or more of serum potassium levels, obtained at any time during 6 months in advance of administration including pre-administration examination, has been 3.6 [1]/L or less.

    3. Hypomagnesemia or suspected be hypomagnesemia: One or more of serum magnesium levels, obtained at any time during 6 months in advance of administration including pre-administration examination, has been 1.8 mg/dL or less.
    4. T-wave abnormality of electrocardiogram at the time of sinus rhythm
    5. Past medical history as fainting; syncope with unknown etiology or complicating illness.
    6. Past own medical history or family medical history as long syndrome (4) Severe heart hypertrophy; Cardiomegaly: Septal Thickness of cardiac ultrasound has been exceeded over 15 mm.

      (5) Left atrial dimension (parasternal long-axis view) of cardiac ultrasound has been exceeded over 45 mm.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    M201-A Injection

    Active Substance: M201-A Route of administration: continuous intravenous injection

    Drug: M201-A Injection

  • Placebo comparator
    Placebo

    Saline Placebo for M201-A Route of administration: continuous intravenous injection

    Drug: Placebo

Interventions

  • DrugM201Studies of M201M201 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Active Substance: M201-A Route of administration: continuous intravenous injection Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)

  • DrugPlacebo

    Saline Placebo: M201-A Placebo Route of administration: continuous intravenous injection Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)

06

What researchers measure

Primary outcomes

  1. Safety Assessment

    Safety investigation based on combined Investigator examination, Adverse Events (particulary, incidence of abnormal laboratory tests,abnormal vital sings,abnormal 12-lead ECG, abnormal 24-hour Holter ECG)

    Time frame: throughout the study duration(up to day7)

  2. Arrest of atrial fibrillation (AF)

    Ratio of arrested AF\* in administered subjects within 2 hours after administration (\*Restoration of sinus rhythm should be kept at least one(1) minute or more.)

    Time frame: throughout the study duration(Within 2 hours)

07

Study locations

5 of 5 sites recruiting
  • Koga general Hospital
    Koga-City, Ibaraki 306-0041, Japan
    Recruiting
    • Koji Uchida · Contactuchida@kogahosp.jp · +81280471010
    • Masataka Fukue · Principal investigator
    • Tetsuya Ishikawa · Sub investigator
  • Kitasato University Hospital
    Sagamihara-city, Kanagawa 252-0375, Japan
    Recruiting
    • Kimiko Yamamura · Contactkimiko-y@kitasato-u.ac.jp · +81427788462
    • Junya Ako · Principal investigator
    • Takao Shimohama · Sub investigator
    • Hidehira Fukaya · Sub investigator
    • Jun Kishihara · Sub investigator
    • Jun Oikawa · Sub investigator
    • Naruya Ishizue · Sub investigator
  • Sendai Cardiovascular Center
    Sendai-city, Miyagi 981-3133, Japan
    Recruiting
    • Masahiro Yagi · Contactccuami@star.gmobb.jp · +81223721111
    • Masahiro Yagi · Principal investigator
    • Tatsuro Uchida · Sub investigator
    • Shinya Fujii · Sub investigator
    • Hiroshi Kobayashi · Sub investigator
    • Shoko Uematsu · Sub investigator
    • Chikahiko Koeda · Sub investigator
    • Yukako Tanaka · Sub investigator
    • Satoshi Miyazawa · Sub investigator
    • Ryozo Maeda · Sub investigator
    • JIHAENG Im · Sub investigator
  • Dokkyo Medical University Saitama Medical Center
    Koshigaya-city,, Saitama 343-8555, Japan
    Recruiting
    • Mariko Iyama · Contactm-iyama@dokkyomed.ac.jp · +81489650658
    • Shiro Nakahara · Principal investigator
    • Reiko Fukuda · Sub investigator
    • Naoki Nishiyama · Sub investigator
    • Yuri Koshikawa · Sub investigator
    • Tomoaki Ukaji · Sub investigator
  • Yamanashi Prefectural Central Hospital
    Kofu-city, Yamanashi 400-8506, Japan
    Recruiting
    • Masahiko Nakamura · Contactm-nakamura@ych.pref.yamanashi.jp · +81552537111
    • Masahiko Nakamura · Principal investigator
    • Ken Umetani · Sub investigator
    • Keita Sano · Sub investigator
    • Aritaka Makino · Sub investigator
    • Toshiaki Yano · Sub investigator
    • Takuya Shimizu · Sub investigator
    • Serina Ono · Sub investigator
    • Chisa Asahina · Sub investigator
    • Koki Fukasawa · Sub investigator
    • Miu Eguchi · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Oct 2019, 4 months.

Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2020
First posted
Oct 30, 2020
StartActual
May 7, 2019
Primary completionActual
Oct 1, 2019
CompletionEst.
Dec 31, 2020
Last update
Oct 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04609059
Lead sponsor
Kitasato University
Collaborators
Aetas Pharma Co. Ltd.
Responsible party
Yuji KUMAGAI (Yuji KUMAGAI, Professor, Kitasato University, Kitasato University) — Principal investigator
First posted
Oct 30, 2020
Start date
May 7, 2019
Primary completion
Oct 1, 2019
Completion
Dec 31, 2020 (estimated)
Last update
Oct 30, 2020

Study contacts

Miwa Nonaka
Contact
m201-a@insti.kitasato-u.ac.jp
+81357916398

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: M201

Start the discussion